Anika Therapeutics (ANIK) Tops Q3 EPS by 35c
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $20.89 --0%
EPS Growth %: -25.0%
Financial Fact:
Product revenue: 25.78M
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: -25.0%
Financial Fact:
Product revenue: 25.78M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q3 EPS of $0.00, $0.35 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $41.5 million versus the consensus estimate of $38.27 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
- Oppenheimer Starts Amneal Pharmaceuticals (AMRX) at Outperform
- Goldman Sachs Downgrades Bank Mandiri (BMRI:IJ) (PPERF) to Sell, 'Liquidity and capital tightness'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
